8-K: Stoke Therapeutics Q2 2026: Zorevunersen Trial Progress

Stoke Therapeutics reported Q2 2026 financial results, detailing advancements in its Phase 3 EMPEROR study for zorevunersen in Dravet syndrome and its Phase 1 OSPREY study for STK-002 in ADOA, supported by a robust cash runway.

Summary

• Stoke Therapeutics announced its financial results for the second quarter ended June 30, 2026.
• The company reported $420 million in cash, cash equivalents, and marketable securities, expected to fund operations through early 2028.
• Enrollment for the Phase 3 EMPEROR study of zorevunersen in Dravet syndrome is complete with 162 patients.
• A pre-NDA meeting with the FDA is scheduled for H2 2026, with a rolling U.S. NDA submission planned for Q1 2027.
• Data readout for the EMPEROR study is anticipated in Q3 2027, with completion of the rolling NDA submission expected in H2 2027.
• The Phase 1 OSPREY study of STK-002 for ADOA has completed dosing in the sentinel cohort, with dose escalation continuing and initial data expected in H1 2027.
• Revenue for Q2 2026 was $9.3 million, a decrease from $13.8 million in Q2 2025.
• Net loss for Q2 2026 was $61.6 million, or $0.93 per share, compared to a net loss of $23.5 million, or $0.40 per share, in Q2 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic report, highlighting significant clinical trial progress and a strong cash position, while acknowledging increased operating expenses and a net loss.

Positives

• Enrollment of 162 patients in the Phase 3 EMPEROR study for zorevunersen is complete.
• No treatment discontinuations have occurred in the EMPEROR study to date.
• The company has approximately $420 million in cash, cash equivalents, and marketable securities, providing runway through potential U.S. commercialization of zorevunersen in early 2028.
• The Phase 1 OSPREY study for STK-002 has completed dosing in the sentinel cohort with no serious or severe safety events observed.
• Zorevunersen has received Breakthrough Therapy Designation from the FDA and China's Center for Drug Evaluation.
• Zorevunersen has received Orphan Drug Designation from the FDA and EMA, and Rare Pediatric Disease Designation from the FDA.

Negatives

• Revenue for Q2 2026 decreased to $9.3 million from $13.8 million in Q2 2025.
• Net loss for Q2 2026 increased to $61.6 million ($0.93/share) from $23.5 million ($0.40/share) in Q2 2025.
• Research and development expenses increased to $49.5 million in Q2 2026 from $25.9 million in Q2 2025.
• Sales, general, and administrative expenses increased to $25.3 million in Q2 2026 from $15.3 million in Q2 2025.
• Revenue for the six months ended June 30, 2026, decreased significantly to $15.6 million from $172.4 million in the same period of 2025, primarily due to a large IP license recognition in the prior year.

Risks

• The potential that positive results in a clinical trial may not be replicated in subsequent trials or successes in early-stage clinical trials may not be predictive of results in later-stage trials.
• The company's ability to advance, obtain regulatory approval for, and ultimately commercialize its product candidates.
• The possibility that the company and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen.
• Risks related to the company's ability to protect its intellectual property.
• Risks related to the company's ability to fund development activities and achieve development goals into 2028.
• The potential for delays in clinical trial timelines, regulatory submissions, or decisions.

Future Outlook

The company expects its current cash position to fund operations through to the potential U.S. commercialization of zorevunersen in early 2028. Key milestones include a pre-NDA meeting with the FDA in H2 2026, initiation of a rolling U.S. NDA submission in Q1 2027, and data readouts for both zorevunersen and STK-002 in 2027.

Management Comments

• "We have made significant progress across our business this year, including the rapid enrollment of 162 patients into the Phase 3 EMPEROR study and progression of these patients through key study milestones with the first patients now approaching the end of the 52-week treatment period."
• "With no treatment discontinuations to date in EMPEROR, and supportive four-year safety and efficacy data from the ongoing open-label extension studies, we have confidence in the potential of zorevunersen to change the course of Dravet syndrome."
• "We look forward to our upcoming pre-NDA meeting with the FDA to align on the overall data package content and timing, as well as the statistical analysis plan, as we prepare to initiate our rolling U.S. NDA submission in the first quarter of 2027."
• "Beyond Dravet syndrome, we are advancing our pipeline. Dose escalation continues in our Phase 1 study of STK-002 in patients with ADOA and initial data are anticipated in the first half of 2027 to guide future clinical development."
• "We are also expanding our early research efforts to identify new haploinsufficient disease targets, and we recently strengthened our leadership team with the addition of Tom McCauley as Chief Scientific Officer to help guide this next phase of platform expansion and translational research."
• "In parallel we continue to enhance our commercial capabilities, enabled by our strong financial position of approximately $420 million that will take us through to a potential U.S. launch of zorevunersen by early 2028 and support the Company's next phase of growth."

Industry Context

StockSavvy.ai notes that Stoke Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on rare genetic diseases. The company's progress with zorevunersen aligns with the industry trend towards developing disease-modifying therapies rather than just symptomatic treatments. The significant increase in R&D and SG&A expenses reflects the typical investment required for late-stage clinical development and pre-commercialization activities in this field.

Comparison to Industry Standards

• The cash runway extending through early 2028 for a company at this stage of clinical development (Phase 3 for lead asset) is generally considered strong within the biotech industry, especially for companies developing treatments for rare diseases.
• The net loss of $61.6 million in Q2 2026 is substantial but aligns with industry norms for companies investing heavily in late-stage clinical trials and pipeline expansion.
• The revenue decrease from $13.8M to $9.3M in Q2 is notable, but the significant drop in year-to-date revenue from $172.4M to $15.6M is primarily attributed to a large one-time revenue recognition event in the prior year related to a Biogen IP license, which is not uncommon in biotech collaborations.
• The increase in R&D and SG&A expenses is consistent with companies advancing multiple drug candidates towards regulatory submission and potential commercialization.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact from continued progress in late-stage clinical trials and strong cash position, potentially leading to future commercialization. Negative impact from increased net loss and revenue decline in the quarter.
• Patients with Dravet syndrome: Potential for a first-in-class disease-modifying treatment (zorevunersen) with positive trial enrollment and progress.
• Patients with ADOA: Continued development of STK-002 offers hope for a potential first disease-modifying therapy.
• Employees: Increased R&D and SG&A expenses suggest continued investment in personnel and growth.
• Partners (Biogen, Acadia): Progress in collaborations is crucial for future revenue and development milestones.

Next Steps

• Complete enrollment in the additional European cohort for zorevunersen (expected August 2026).
• Initiate dosing in the second cohort of the Phase 1 OSPREY study (expected August 2026).
• Participate in a pre-NDA meeting with the FDA for zorevunersen (H2 2026).
• Initiate rolling U.S. NDA submission for zorevunersen (Q1 2027).
• Report initial data from the Phase 1 OSPREY study (H1 2027).
• Report data from the Phase 3 EMPEROR study (Q3 2027).
• Complete rolling U.S. NDA submission for zorevunersen (H2 2027).
• Potential U.S. commercialization of zorevunersen (early 2028).

Key Dates

Recommendation

The company is making significant clinical progress with its lead candidate, zorevunersen, and maintains a strong cash position. However, the increased net loss, revenue decline (though partially explained by prior year events), and the long timelines to potential commercialization warrant a cautious 'hold' rating. Investors should monitor upcoming data readouts and regulatory milestones closely.

Keywords

Dravet syndrome, zorevunersen, RNA medicine, biotechnology, clinical trials, ADOA, STK-002, FDA